Qube Research & Technologies LTD Cardiff Oncology, Inc. Transaction History
Qube Research & Technologies LTD
- $62.3 Billion
- Q2 2024
A detailed history of Qube Research & Technologies LTD transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 40,664 shares of CRDF stock, worth $102,879. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,664
Previous 127,283
68.05%
Holding current value
$102,879
Previous $679,000
86.75%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CRDF
# of Institutions
97Shares Held
12.8MCall Options Held
823KPut Options Held
78K-
Black Rock Inc. New York, NY2.63MShares$6.65 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.14MShares$5.4 Million0.0% of portfolio
-
Assenagon Asset Management S.A.1.22MShares$3.08 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA911KShares$2.3 Million0.0% of portfolio
-
State Street Corp Boston, MA805KShares$2.04 Million0.0% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $110M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...